Investigating how to inhibit drug resistance in Candida glabrata
Official title: Chemical genetic analysis of Candida glabrata CDR1 expression
Funded at University of Iowa · NIH-10734781 · Data updated 2026-11-12
This study is looking at how the Candida glabrata fungus becomes resistant to antifungal medicines, especially azole drugs, and aims to find new ways to help patients with these infections by discovering small molecules that can stop this resistance from happening.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | November 4, 2022 |
| Project end | October 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $194,375 |
| NIH project number | 5R21AI168509-02 |
| Project ID | NIH-10734781 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from infections caused by Candida glabrata, particularly those who have shown resistance to azole antifungal drugs.
✕Less likely to help
Patients with infections caused by other types of fungi or those who do not have Candida glabrata infections may not benefit from this research.
What this research studies
This research focuses on understanding how the Candida glabrata fungus develops resistance to antifungal medications, particularly azole drugs. By examining specific genetic mutations that lead to increased expression of a drug efflux pump, the study aims to identify small molecules that can inhibit this resistance mechanism. Patients with infections caused by Candida glabrata may benefit from new treatment strategies developed through this research. The approach involves screening chemical libraries to find compounds that can effectively block the activation of resistance genes.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the effectiveness of existing antifungal treatments for patients with Candida glabrata infections.
How similar studies have gone: Other research has shown promise in targeting drug resistance mechanisms in fungi, suggesting that this approach could yield significant advancements.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Moye-Rowley, W Scott — University of Iowa
- Study coordinator: Moye-Rowley, W Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.